154 related articles for article (PubMed ID: 35581303)
1. The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.
Sakamoto K; Lin B; Nunomura K; Izawa T; Nakagawa S
Sci Rep; 2022 May; 12(1):8121. PubMed ID: 35581303
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.
Sakamoto K; Qi Y; Miyako E
Sci Rep; 2023 Jan; 13(1):518. PubMed ID: 36627374
[TBL] [Abstract][Full Text] [Related]
3. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K; Masutani T; Hirokawa T
Sci Rep; 2020 Dec; 10(1):21671. PubMed ID: 33303890
[TBL] [Abstract][Full Text] [Related]
4. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
5. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
6. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
7. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
Kumar SU; Priya Doss CG
Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
[TBL] [Abstract][Full Text] [Related]
8. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
9. ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells.
Botta GP; Reichert M; Reginato MJ; Heeg S; Rustgi AK; Lelkes PI
Neoplasia; 2013 Apr; 15(4):359-72. PubMed ID: 23555182
[TBL] [Abstract][Full Text] [Related]
10. Loss of protein phosphatase 6 in mouse keratinocytes enhances K-ras
Kurosawa K; Inoue Y; Kakugawa Y; Yamashita Y; Kanazawa K; Kishimoto K; Nomura M; Momoi Y; Sato I; Chiba N; Suzuki M; Ogoh H; Yamada H; Miura K; Watanabe T; Tanuma N; Tachi M; Shima H
Cancer Sci; 2018 Jul; 109(7):2178-2187. PubMed ID: 29758119
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
[TBL] [Abstract][Full Text] [Related]
12. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
13. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.
Niida A; Sasaki S; Yonemori K; Sameshima T; Yaguchi M; Asami T; Sakamoto K; Kamaura M
Bioorg Med Chem Lett; 2017 Jun; 27(12):2757-2761. PubMed ID: 28457754
[TBL] [Abstract][Full Text] [Related]
15. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
16. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.
Salaymeh Y; Farago M; Sebban S; Shalom B; Pikarsky E; Katzav S
Life Sci Alliance; 2020 May; 3(5):. PubMed ID: 32277014
[TBL] [Abstract][Full Text] [Related]
17. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
18. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
19. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
[TBL] [Abstract][Full Text] [Related]
20. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]